Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fadrozole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 15/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 9/20 | 1.00 |
| ▸ | CYP11B1 | P15538 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fadrozole SCHEMBL3295820 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| S-Fadrozole SCHEMBL13449014 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Dexfadrostat SCHEMBL685516 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Fadrozole SCHEMBL122801 | 0.99 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Fadrozole SCHEMBL9739941 | 0.99 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Fadrozole SCHEMBL4143 | 0.99 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Dexfadrostat SCHEMBL4619633 | 0.99 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Fadrozole SCHEMBL1650121 | 0.97 | CYP19A1 (0.95) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL2351202 | 0.96 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Dexfadrostat SCHEMBL23064072 | 0.93 | CYP19A1 (0.86) | CYP19A1CYP11B2CYP11B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 32725 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-3645742-B1 | ANTI-ROR1 ANTIBODIES AND METHODS OF MAKING AND USING THEREOF | SYSTIMMUNE INC (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260103461-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | OLEMA PHARMACEUTICALS INC (US) | 2026-04-16 | — | — | US | claimed |
| EP-4712980-A1 | TREATMENT OF BREAST TISSUE | Havah Therapeutics Pty Ltd (AU) | 2026-03-25 | — | — | EP | claimed |
| US-12576077-B2 | Composition for preventing, alleviating or treating cancer | CKP THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4680226-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | Olema Pharmaceuticals, Inc. (US) | 2026-01-21 | — | — | EP | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4653019-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE FOR TREATING BREAST CANCER | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-11-26 | — | — | EP | claimed |
| EP-4643858-A1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF UTERINE DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-11-05 | — | — | EP | claimed |
| EP-0514015-A1 | Control of sex differentiation in fish | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | claimed |
| US-5162337-A | Administering Steroid Biosynthesis Inhibitors | MERCK & CO., INC. (US) | 1992-11-10 | — | — | US | claimed |
| EP-0479570-A2 | Animal growth promotion with aromatase inhibitors | MERCK & CO. INC. (US) | 1992-04-08 | — | — | EP | claimed |
| US-5057521-A | USE OF BICYCLIC IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HYPERALDOSTERONISM | CIBA-GEIGY CORPORATION (US) | 1991-10-15 | — | — | US | claimed |
| EP-0437415-A2 | Crystalline form of the hydrochloride of 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)-benzonitrile | CIBA-GEIGY AG (CH) | 1991-07-17 | — | — | EP | claimed |
| EP-0433084-A2 | Use of aromatese inhibitors for the reversal of female sexual phenotype in poultry | MERCK & CO. INC. (US) | 1991-06-19 | — | — | EP | claimed |
| EP-0165904-B1 | SUBSTITUTED BICYCLE COMPOUNDS | CIBA-GEIGY AG (CH) | 1991-04-10 | — | — | EP | claimed |
| US-4889861-A | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors | CIBA-GEIGY CORP. (US) | 1989-12-26 | — | — | US | claimed |
| US-4617307-A | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors | CIBA-GEIGY CORPORATION (US) | 1986-10-14 | — | — | US | claimed |
| EP-0165904-A2 | Substituted bicycle compounds | CIBA-GEIGY AG (CH) | 1985-12-27 | — | — | EP | claimed |